A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
Special interests vs. the public interest: The cost of STR restrictions on households, cities, and visitors
STRs have provided a competitive alternative to hotels, helping owners earn income and afford their homes. They also support local jobs and businesses and...